People · Operator
Named in public records as an officer, director or promoter · active 2014–2021 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Antiva Biosciences, Inc. | — | Biotechnology | Series B | $96.8M | $457.8M | 2021 |
| Navitor Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $68.2M | $686.4M | 2020 |
| Therabron Therapeutics, Inc. | — | Biotechnology | Series A | $15.6M | $84.1M | 2014 |
| Tyrogenex, Inc. | — | Biotechnology | Series A | $14.6M | $19.7M | 2016 |
Vinzenz Ploerer at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Vinzenz Ploerer on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Vinzenz P. Ploerer | 2 | 2 |
| Jean-Francois Formela | 1 | 17 |
| Wende Hutton | 1 | 16 |
| Kevin Bitterman | 1 | 15 |
| Brian Gallagher | 1 | 11 |
| Alan Crane | 1 | 9 |
| Todd Brady | 1 | 7 |
| David Kabakoff | 1 | 7 |
| Rajeev Dadoo | 1 | 7 |
| Michael Webb | 1 | 6 |
| John Creecy | 1 | 5 |
| Paul Friedman | 1 | 5 |
| Marian Nakada | 1 | 4 |
| Michael J Sullivan | 1 | 4 |
| THOMAS HUGHES | 1 | 4 |
| Michael Cannon | 1 | 4 |
| SHERIDAN G. SNYDER | 1 | 3 |
| Steven James | 1 | 3 |
| David Madden | 1 | 3 |
| Jenny Yip | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.